Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 5.51B | 5.37B | 4.80B | 4.35B | 5.12B | 4.64B |
Gross Profit | 2.01B | 2.47B | 933.50M | 4.15B | 4.91B | 4.44B |
EBITDA | 1.25B | 1.19B | 1.02B | 873.80M | 879.00M | 815.20M |
Net Income | 494.70M | 455.70M | 352.00M | 271.00M | 412.20M | 284.20M |
Balance Sheet | ||||||
Total Assets | 6.64B | 6.53B | 6.10B | 5.64B | 6.86B | 6.45B |
Cash, Cash Equivalents and Short-Term Investments | 95.80M | 85.40M | 69.10M | 21.80M | 54.80M | 224.00M |
Total Debt | 2.70B | 2.71B | 2.93B | 2.99B | 3.54B | 3.54B |
Total Liabilities | 3.70B | 3.69B | 3.81B | 3.77B | 4.47B | 4.44B |
Stockholders Equity | 2.16B | 2.07B | 1.65B | 1.31B | 1.91B | 1.59B |
Cash Flow | ||||||
Free Cash Flow | 386.40M | 360.30M | 267.70M | 121.70M | 164.60M | 296.50M |
Operating Cash Flow | 1.05B | 1.00B | 850.80M | 705.80M | 715.80M | 704.70M |
Investing Cash Flow | -700.50M | -512.90M | -602.80M | -627.00M | -666.30M | -407.50M |
Financing Cash Flow | -541.70M | -330.60M | -197.20M | -145.70M | -240.10M | -145.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $11.69B | 10.19 | 18.35% | 0.44% | 9.73% | 51.87% | |
77 Outperform | $16.49B | 24.63 | 4.36% | 2.82% | -0.91% | 27.17% | |
75 Outperform | $12.03B | 24.65 | 25.33% | 0.57% | 11.21% | 30.38% | |
71 Outperform | $16.01B | 11.33 | 38.12% | ― | -1.79% | -41.85% | |
66 Neutral | $6.82B | 22.70 | 26.11% | 0.43% | 8.52% | 10.36% | |
66 Neutral | $10.78B | 14.23 | 260.92% | ― | 5.11% | 14.28% | |
46 Neutral | C$198.48M | -3.49 | -23.22% | 2.62% | 21.07% | -1.26% |
Encompass Health has published its Investor Reference Book, highlighting the importance of non-GAAP financial measures like Adjusted EBITDA and adjusted free cash flow in assessing its financial performance and liquidity. These measures are crucial for understanding the company’s ability to service debt and make capital expenditures. The company emphasizes the significance of maintaining compliance with financial covenants in its credit agreements, as noncompliance could lead to financial restrictions. Encompass Health’s strategic focus on growth through new developments and acquisitions, alongside its financial strength, positions it well in the healthcare industry, despite potential risks such as regulatory changes and market pressures.
The most recent analyst rating on (EHC) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Encompass Health stock, see the EHC Stock Forecast page.
Encompass Health has provided a financial update regarding its inability to predict certain non-GAAP financial measures due to factors outside its control, such as government settlements and market conditions. The company has estimated specific GAAP measures for 2025, including interest expense and amortization of debt-related items, which will be part of a reconciliation for Adjusted EBITDA.
The most recent analyst rating on (EHC) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Encompass Health stock, see the EHC Stock Forecast page.
On May 1, 2025, Encompass Health Corporation’s stockholders approved the 2025 Omnibus Performance Incentive Plan during the annual meeting. The meeting also saw the election of ten directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation, reflecting strong shareholder support for the company’s strategic direction.
On April 24, 2025, Encompass Health announced the appointment of Patrick W. Tuer as Executive Vice President and Chief Operating Officer. Mr. Tuer has been with the company since 2018, holding various leadership roles, and his promotion reflects his significant contributions to the company’s operations. In the first quarter of 2025, Encompass Health reported a 10.6% increase in revenue, driven by higher discharges and pricing, and a 14.9% rise in Adjusted EBITDA. The company also raised its full-year guidance, indicating strong performance and positive future prospects.